NASDAQ:CBDC

Apotheca Biosciences Competitors

$0.08
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.08
Now: $0.08
$0.08
50-Day Range
$0.01
MA: $0.05
$0.09
52-Week Range
$0.00
Now: $0.08
$0.31
Volume2,400 shs
Average Volume20,137 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Apotheca Biosciences (NASDAQ:CBDC) Vs. ABCL, SANA, ABCM, SEER, NUVB, and IBRX

Should you be buying CBDC stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Apotheca Biosciences, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

Apotheca Biosciences (NASDAQ:CBDC) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Apotheca Biosciences and AbCellera Biologics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apotheca BiosciencesN/AN/AN/AN/AN/A
AbCellera BiologicsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Apotheca Biosciences and AbCellera Biologics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apotheca Biosciences0000N/A
AbCellera Biologics00503.00

AbCellera Biologics has a consensus price target of $52.80, suggesting a potential upside of 86.24%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and AbCellera Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apotheca BiosciencesN/AN/AN/A
AbCellera BiologicsN/AN/AN/A

Summary

AbCellera Biologics beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Sana Biotechnology and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
Apotheca BiosciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sana Biotechnology and Apotheca Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Apotheca Biosciences0000N/A

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 27.47%. Given Sana Biotechnology's higher possible upside, equities research analysts clearly believe Sana Biotechnology is more favorable than Apotheca Biosciences.

Profitability

This table compares Sana Biotechnology and Apotheca Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
Apotheca BiosciencesN/AN/AN/A

Summary

Sana Biotechnology beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Abcam and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Apotheca BiosciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Apotheca Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Apotheca Biosciences0000N/A

Abcam currently has a consensus target price of $22.00, suggesting a potential upside of 10.61%. Given Abcam's higher possible upside, equities research analysts clearly believe Abcam is more favorable than Apotheca Biosciences.

Profitability

This table compares Abcam and Apotheca Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Apotheca BiosciencesN/AN/AN/A

Summary

Abcam beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Seer and Apotheca Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Apotheca Biosciences0000N/A

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 30.79%. Given Seer's higher possible upside, equities research analysts clearly believe Seer is more favorable than Apotheca Biosciences.

Profitability

This table compares Seer and Apotheca Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Apotheca BiosciencesN/AN/AN/A

Valuation & Earnings

This table compares Seer and Apotheca Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Apotheca BiosciencesN/AN/AN/AN/AN/A

Summary

Seer beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Apotheca Biosciences (NASDAQ:CBDC) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for Apotheca Biosciences and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apotheca Biosciences0000N/A
Nuvation Bio00603.00

Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apotheca BiosciencesN/AN/AN/A
Nuvation BioN/AN/AN/A

Earnings & Valuation

This table compares Apotheca Biosciences and Nuvation Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apotheca BiosciencesN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.

Apotheca Biosciences (NASDAQ:CBDC) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for Apotheca Biosciences and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apotheca Biosciences0000N/A
ImmunityBio00103.00

ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 48.19%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Apotheca Biosciences.

Profitability

This table compares Apotheca Biosciences and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apotheca BiosciencesN/AN/AN/A
ImmunityBioN/AN/AN/A

Earnings & Valuation

This table compares Apotheca Biosciences and ImmunityBio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apotheca BiosciencesN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Apotheca Biosciences on 2 of the 2 factors compared between the two stocks.


Apotheca Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$28.35flat$7.64 billionN/A0.00Gap Up
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$31.38flat$5.88 billionN/A0.00Gap Down
Abcam logo
ABCM
Abcam
1.5$19.89flat$4.51 billionN/A0.00
SEER
Seer
1.2$51.99flat$3.17 billionN/A0.00Gap Down
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00flat$2.18 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.87flat$1.84 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.5$47.35flat$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47flat$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30flat$1.41 billionN/A0.00News Coverage
EWTX
Cricut
0.3$29.54flat$1.41 billionN/A0.00News Coverage
KNTE
Kinnate Biopharma
1.7$31.55flat$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07flat$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12flat$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02flat$1.19 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.69flat$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00flat$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01flat$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32flat$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50flat$885.10 millionN/A0.00Analyst Downgrade
PHAR
Pharming Group
0.0$13.26flat$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19flat$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18flat$809.95 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22flat$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
SGTX
Sigilon Therapeutics
1.4$17.76flat$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44flat$557.76 millionN/A0.00
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93flat$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48flat$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13flat$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85flat$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93flat$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23flat$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83flat$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07flat$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00flat$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54flat$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28flat$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54flat$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98flat$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06flat$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81flat$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09flat$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64flat$100.92 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$15.66flat$61.20 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62flat$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17flat$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87flat$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66flat$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86flat$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90flat$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Up
VYNT
Vyant Bio
0.0$4.02flat$16.42 millionN/A0.00Gap Down
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.